Company Overview

Update
Headquarters:
Finans
Funding:
$143.80M
Categories:
Biotechnology

Biotie is a specialized drug development company focused on the central nervous system and inflammatory diseases.

Description

Update

Biotie is a specialized drug development company focused on central nervous system and inflammatory diseases. It has several innovative small molecule and biological drug candidates at different stages of clinical development. Biotie's products address diseases with high unmet medical need and significant market potential, including addiction and a broad range of inflammatory conditions such as rheumatoid arthritis and chronic obstructive pulmonary disease (COPD). The most advanced product, nalmefene for alcohol dependence, is currently in phase III clinical development by licensing partner H. Lundbeck A/S.

Current Team (3)

Update

Board Members and Advisors (1)

Update

Acquisitions (2)

Update

Funding Rounds (1) - $143.80M

Update
  • $143.80M

    Investors Unknown
    Jun 26, 2013 -Grant

Offices/Locations (1)

Update
  • Office

    Tykistökatu 6

    Finans, FI-20520

    FIN